Fetal Release of Copeptin in Response to Maternal Oxytocin Administration: A Randomized Controlled Trial

Sven Wellmann, Andrea Koslowski, Katharina Spanaus, Roland Zimmermann, Tilo Burkhardt, Sven Wellmann, Andrea Koslowski, Katharina Spanaus, Roland Zimmermann, Tilo Burkhardt

Abstract

Objective: To test whether an oxytocin challenge test raises neonatal levels of copeptin, the C-terminal portion of proarginine vasopressin, a sensitive stress marker elevated in neonates born by vaginal delivery as opposed to elective cesarean delivery.

Methods: In a randomized controlled trial in women with a singleton pregnancy undergoing elective cesarean delivery at greater than 36 weeks of gestation and no contractions or rupture of membranes, we compared arterial umbilical cord plasma concentrations of copeptin between neonates exposed to an oxytocin challenge test before elective cesarean delivery and those administered saline infusion (placebo group). Women randomized to an oxytocin challenge test received 5 international units/500 mL oxytocin Ringer lactate infused at a rate of 12 mL/h and doubled every 10 minutes until it induced three uterine contractions per 10-minute interval, at which point it was discontinued. Neonatal copeptin levels were the primary endpoint. Secondary endpoints included biochemical and physiologic parameters of fetal and maternal well-being.

Results: From January 2012 to October 2012 and from September 2013 to January 2015, 78 women underwent an oxytocin challenge test and 78 placebo infusion, of whom 12 and 11, respectively, were excluded as a result of insufficient blood sample volume for analysis. Umbilical cord plasma copeptin levels [median (range)] were higher in neonates who underwent an oxytocin challenge test than those who underwent placebo infusion: 22.2 (3.22-2,319) compared with 7.39 (2.5-344.6) pmol/L (P<.001). There were no statistically significant differences between the two groups in secondary outcomes.

Conclusion: Oxytocin challenge test-induced contractions before elective cesarean delivery trigger fetal copeptin release.

Clinical trial registration: ClinicalTrials.gov, https://ichgcp.net/clinical-trials-registry/NCT01962701" title="See in ClinicalTrials.gov">NCT01962701.

References

    1. Schuetz P, Christ-Crain M, Müller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:578–85.
    1. Katan M, Morgenthaler N, Widmer I, Puder JJ, König C, Müller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008;29:341–6.
    1. Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012;10:7.
    1. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112–9.
    1. Wellmann S, Benzing J, Cippà G, Admaty D, Creutzfeldt R, Mieth RA, et al. High copeptin concentrations in umbilical cord blood after vaginal delivery and birth acidosis. J Clin Endocrinol Metab 2010;95:5091–6.
    1. Benzing J, Wellmann S, Achini F, Letzner J, Burkhardt T, Beinder E, et al. Plasma copeptin in preterm infants: a highly sensitive marker of fetal and neonatal stress. J Clin Endocrinol Metab 2011;96:E982–5.
    1. Schlapbach LJ, Frey S, Bigler S, Manh-Nhi C, Aebi C, Nelle M, et al. Copeptin concentration in cord blood in infants with early-onset sepsis, chorioamnionitis and perinatal asphyxia. BMC Pediatr 2011;11:38.
    1. Smith J, Halse KG, Damm P, Lindegaard ML, Amer-Wåhlin I, Hertel S, et al. Copeptin and MR-proADM in umbilical cord plasma reflect perinatal stress in neonates born to mothers with diabetes and MR-proANP reflects maternal diabetes. Biomark Med 2013;7:139–46.
    1. Burkhardt T, Schwabe S, Morgenthaler NG, Natalucci G, Zimmermann R, Wellmann S. Copeptin: a marker for stress reaction in fetuses with intrauterine growth restriction. Am J Obstet Gynecol 2012;207:497.e1–5.
    1. Burckhardt MA, Wellmann M, Fouzas S, Lapaire O, Burkhardt T, Benzing J, et al. Sexual disparity of copeptin in healthy newborn infants. J Clin Endocrinol Metab 2014;99:E1750–3.
    1. L'Abate P, Wiegert S, Struck J, Wellmann S, Cannizzaro V. Determinants of plasma copeptin: a systematic investigation in a pediatric mechanical ventilation model. Respir Physiol Neurobiol 2013;185:222–7.
    1. Ostergaard L, Rudiger A, Wellmann S, Gammella E, Beck-Schimmer B, Struck J, et al. Arginine-vasopressin marker copeptin is a sensitive plasma surrogate of hypoxic exposure. Hypoxia 2014;2:143–51.
    1. Schmidt S, Langner K, Dudenhausen JW, Saling E. Measurement of transcutaneous pCO2 and pO2 in the fetus during labor. Arch Gynecol 1985;236:145–51.
    1. Rooth G, Fall O, Huch A, Huch R. Integrated interpretation of fetal heart rate, intrauterine pressure and fetal transcutaneous PO2. Gynecol Obstet Invest 1979;10:265–80.
    1. Klink F, Grosspietzsch R, Klitzing LV, Oberheuser F. Uterine contraction intervals and transcutaneous levels of fetal oxygen pressure. Obstet Gynecol 1981;57:437–40.
    1. Pimentel G, Poore ER, Nathanielsz PW. The effect of continuous or pulsatile administration of oxytocin to ewes at 126 to 136 days' gestation on myometrial activity and fetal oxygenation. Am J Obstet Gynecol 1989;160:242–7.
    1. Shinozuka N, Yen A, Nathanielsz PW. Alteration of fetal oxygenation and responses to acute hypoxemia by increased myometrial contracture frequency produced by pulse administration of oxytocin to the pregnant ewe from 96 to 131 days' gestation. Am J Obstet Gynecol 1999;180:1202–8.
    1. DeVane GW, Naden RP, Porter JC, Rosenfeld CR. Mechanism of arginine vasopressin release in the sheep fetus. Pediatr Res 1982;16:504–7.
    1. Rurak DW. Plasma vasopressin levels during hypoxaemia and the cardiovascular effects of exogenous vasopressin in foetal and adult sheep. J Physiol 1978;277:341–57.
    1. Carey LC, Tatter SB, Rose JC. Ontogeny and effects of hypothalamic pituitary disconnection on formation of inositol trisphosphate in fetal sheep pituitary cells. Endocrinology 2007;148:1440–4.
    1. Ross MG, Ervin G, Leake RD, Fu P, Fisher DA. Fetal lung liquid regulation by neuropeptides. Am J Obstet Gynecol 1984;150:421–5.
    1. Gibson KJ, Lumbers ER. The roles of arginine vasopressin in fetal sodium balance and as a mediator of the effects of fetal “stress”. J Dev Physiol 1993;19:125–36.
    1. Perks AM, Kindler PM, Marshall J, Woods B, Craddock M, Vonder Muhll I. Lung liquid production by in vitro lungs from fetal guinea pigs: effects of arginine vasopressin and arginine vasotocin. J Dev Physiol 1993;19:203–12.
    1. Albuquerque CA, Nijland MJ, Ross MG. Mechanism of arginine vasopressin suppression of ovine fetal lung fluid secretion: lack of V2-receptor effect. J Matern Fetal Med 1998;7:177–82.
    1. Guetta J, Klorin G, Tal R, Berger G, Ismael-Badarneh R, Bishara B, et al. Vasopressin-2 receptor antagonist attenuates the ability of the lungs to clear edema in an experimental model. Am J Respir Cell Mol Biol 2012;47:583–8.
    1. De Luca R, Boulvain M, Irion O, Berner M, Pfister RE. Incidence of early neonatal mortality and morbidity after late-preterm and term cesarean delivery. Pediatrics 2009;123:e1064–71.
    1. Bailit JL, Gregory KD, Reddy UM, Gonzalez-Quintero VH, Hibbard JU, Ramirez MM, et al. Maternal and neonatal outcomes by labor onset type and gestational age. Am J Obstet Gynecol 2010;202:245.e1–12.
    1. Wilmink FA, Hukkelhoven CW, Lunshof S, Mol BW, van der Post JA, Papatsonis DN. Neonatal outcome following elective cesarean section beyond 37 weeks of gestation: a 7-year retrospective analysis of a national registry. Am J Obstet Gynecol 2010;202:250.e1–8.
    1. Stutchfield P, Whitaker R, Russell I; Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005;331:662.
    1. Ahmed MR, Sayed Ahmed WA, Mohammed TY. Antenatal steroids at 37 weeks, does it reduce neonatal respiratory morbidity? A randomized trial. J Matern Neonatal Med 2015;28:1486–90.
    1. Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, et al. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016;374:1311–20.
    1. Stutchfield PR, Whitaker R, Gliddon AE, Hobson L, Kotecha S, Doull IJ. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed 2013;98:F195–200.
    1. Aiken CE, Fowden AL, Smith GC. Antenatal glucocorticoids prior to cesarean delivery at term. JAMA Pediatr 2014;168:507–8.
    1. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery. Am J Obstet Gynecol 2016 Epub 2016 Mar 15.
    1. Brown LA, Chen M. Vasopressin signal transduction in rat type II pneumocytes. Am J Physiol 1990;258:L301–7.
    1. Cummings JJ, Carlton DP, Poulain FR, Fike CD, Keil LC, Bland RD. Vasopressin effects on lung liquid volume in fetal sheep. Pediatr Res 1995;38:30–5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe